We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+3.33%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$7.83B
AUM Growth
-$147M
Cap. Flow
+$37.6M
Cap. Flow %
0.48%
Top 10 Hldgs %
76.26%
Holding
100
New
11
Increased
18
Reduced
11
Closed
5

Top Buys

Rank Stock Value
1
SMMT icon
Summit Therapeutics
SMMT
+$125M
2
INSM icon
Insmed
INSM
+$125M
3
ALKS icon
Alkermes
ALKS
+$103M
4
BCYC
Bicycle Therapeutics
BCYC
+$101M
5
ALMS
Alumis Inc
ALMS
+$20.8M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$308M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$55.5M
3
ROIV icon
Roivant Sciences
ROIV
+$50.6M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$38.2M
5
AKRO
Akero Therapeutics
AKRO
+$34.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.1%
2 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.3B
$1.86B 23.81%
30,738,524
-5,441,141
-15% -$308M
ONC
2
BeOne Medicines Ltd
ONC
$34.1B
$1.51B 19.27%
10,568,897
– –
ACAD icon
3
Acadia Pharmaceuticals
ACAD
$4.46B
$697M 8.9%
42,877,916
+13,304
+0% +$215K
MDGL icon
4
Madrigal Pharmaceuticals
MDGL
$12.5B
$553M 7.07%
1,974,590
+4,792
+0.2% +$1.14M
RVMD icon
5
Revolution Medicines
RVMD
$38.3B
$294M 3.75%
7,569,090
+19,841
+0.3% +$742K
RYTM icon
6
Rhythm Pharmaceuticals
RYTM
$7.38B
$263M 3.36%
6,398,365
– –
INSM icon
7
Insmed
INSM
$22.5B
$240M 3.06%
3,576,038
+3,233,038
+943% +$125M
BCYC
8
Bicycle Therapeutics
BCYC
$272M
$190M 2.43%
9,399,960
+4,457,137
+90% +$101M
SMMT icon
9
Summit Therapeutics
SMMT
$10.1B
$181M 2.31%
+23,222,222
New +$125M
KYMR icon
10
Kymera Therapeutics
KYMR
$8.68B
$179M 2.29%
5,995,928
– –
EWTX icon
11
Edgewise Therapeutics
EWTX
$4.29B
$105M 1.34%
5,840,059
– –
ALKS icon
12
Alkermes
ALKS
$8.08B
$101M 1.29%
+4,181,751
New +$103M
REPL icon
13
Replimune Group
REPL
$441M
$90.4M 1.16%
10,045,336
+500,000
+5% +$3.48M
DNLI icon
14
Denali Therapeutics
DNLI
$3.8B
$86.6M 1.11%
3,731,695
– –
ABCL icon
15
AbCellera Biologics
ABCL
$1.63B
$81.5M 1.04%
27,525,640
– –
NRIX icon
16
Nurix Therapeutics
NRIX
$2.45B
$81M 1.04%
3,882,125
– –
IMTX icon
17
Immatics
IMTX
$1.18B
$74.9M 0.96%
6,443,398
– –
TRDA icon
18
Entrada Therapeutics
TRDA
$241M
$69.3M 0.89%
4,865,819
– –
RARE icon
19
Ultragenyx Pharmaceutical
RARE
$2.52B
$60.3M 0.77%
1,466,547
– –
STOK icon
20
Stoke Therapeutics
STOK
$1.82B
$59M 0.75%
4,368,443
+1,000,000
+30% +$13.5M
KNSA icon
21
Kiniksa Pharmaceuticals
KNSA
$6.13B
$52.6M 0.67%
2,818,323
+8,746
+0.3% +$164K
IMCR icon
22
Immunocore
IMCR
$1.68B
$51.4M 0.66%
1,515,318
– –
ARGX icon
23
argenx
ARGX
$55.2B
$48.1M 0.62%
111,904
-39,311
-26% -$15M
KOD icon
24
Kodiak Sciences
KOD
$2.43B
$40.7M 0.52%
17,310,490
– –
XENE icon
25
Xenon Pharmaceuticals
XENE
$6.2B
$38.7M 0.5%
993,679
– –
1
2 3 4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Baker Bros. Advisors held 100 positions worth $7.83B, down 1.8% from $7.97B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Baker Bros. Advisors's Q2 2024 filing shows 11 new, 18 increased, 11 reduced and 5 closed positions. Its largest new stake was Summit Therapeutics: 23,222,222 shares worth $181M. The largest sale was Incyte, an estimated $308M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q2 2024 buy was Summit Therapeutics: 23,222,222 shares worth $181M.
  • Baker Bros. Advisors added most to Insmed in Q2 2024, an estimated $125M increase.
  • Baker Bros. Advisors's biggest Q2 2024 reduction was Incyte, cutting an estimated $308M.
  • Baker Bros. Advisors fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $3.23M.
  • Baker Bros. Advisors's ten largest holdings make up 76% of its $7.83B portfolio in Q2 2024.
  • Baker Bros. Advisors opened 11 new positions and closed 5 in Q2 2024.
  • Baker Bros. Advisors's portfolio value fell 1.8% quarter-over-quarter to $7.83B.

Based on Baker Bros. Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.